Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Picked Up by Analysts at TD Cowen

Equities research analysts at TD Cowen started coverage on shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) in a report issued on Friday, Zacks reports. The brokerage set a “strong-buy” rating on the biotechnology company’s stock.

LKFT has been the subject of a number of other reports. Royal Bank Of Canada upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $26.00 to $45.00 in a report on Wednesday, September 23rd. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, October 2nd. Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Thursday. UBS Group raised Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research report on Wednesday, September 23rd. Finally, Morgan Stanley assumed coverage on Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, October 20th. They issued an “equal weight” rating and a $26.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.50.

Lakefront Biotherapeutics American Depositary Shares Stock Up 0.1%

LKFT stock traded up $0.05 during trading hours on Friday, hitting $33.98. The company’s stock had a trading volume of 287,837 shares, compared to its average volume of 265,015. The company has a market capitalization of $2.24 billion, a PE ratio of -24.10 and a beta of 0.22. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $25.68 and a 12 month high of $36.24. The stock has a 50 day moving average price of $30.36 and a two-hundred day moving average price of $29.94.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its quarterly earnings results on Wednesday, November 11th. The biotechnology company reported ($0.05) EPS for the quarter. The firm had revenue of $7.87 million for the quarter. Sell-side analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Alps Advisors Inc. acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter worth about $2,617,000. Marshall Wace LLP bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at approximately $2,326,000. Commonwealth Equity Services LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at approximately $279,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at approximately $248,000. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.